Strata Critical Medical CAO granted 64,191 RSUs

Cohen Amir reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Cohen Amir reported acquisition or exercise transactions in this Form 4 filing.

Strata Critical Medical, Inc. Chief Accounting Officer Amir Cohen received an equity award in the form of 64,191 Restricted Stock Units (RSUs) of Class A common stock, reported at a price of $0.00 per share. After this grant, his directly held stake increased to 181,817 shares.

The RSUs will be settled in common shares as they vest. According to the vesting schedule, 6.25% of the RSUs (rounded down to the nearest whole number) will vest every three months after March 8, 2026, with any remaining unvested RSUs vesting on March 8, 2030, as long as he continues serving the company.

Insider Trade Summary

Grant/Award: 64,191 shares

Grant/Award 1 txn

Insider Cohen Amir

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Class A common stock, $0.0001 par value per share	64,191	$0.00	$0.00

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 181,817 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting: 6.25% of the RSUs (rounded down to the nearest whole number) will vest every 3 months after March 8, 2026, with any remaining unvested RSUs to vest on March 8, 2030, subject to the Reporting Person's continued service to the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Strata Critical Medical (SRTA) disclose about Amir Cohen's equity grant?

Strata Critical Medical reported that Chief Accounting Officer Amir Cohen received 64,191 Restricted Stock Units. These RSUs represent future shares of Class A common stock, subject to a multi‑year vesting schedule tied to his continued service with the company.

How many Strata Critical Medical (SRTA) shares does Amir Cohen own after this Form 4?

After the reported RSU grant, Amir Cohen directly holds 181,817 shares of Strata Critical Medical Class A common stock. This figure reflects his ownership following the award of 64,191 RSUs that will convert into shares as they vest over time.

What is the vesting schedule for Amir Cohen's 64,191 RSUs at Strata Critical Medical (SRTA)?

The 64,191 RSUs vest gradually. Starting after March 8, 2026, 6.25% of the units (rounded down) vest every three months. Any remaining unvested RSUs fully vest on March 8, 2030, conditioned on his continued service to the company.

Did Amir Cohen buy Strata Critical Medical (SRTA) shares on the open market?

No, the transaction reflects a grant of RSUs, not an open‑market purchase. The Form 4 labels the action as a grant or award acquisition at a reported price of $0.00 per share, typical for equity compensation awards to executives.

What type of security did Strata Critical Medical (SRTA) grant to Amir Cohen?

The company granted Restricted Stock Units linked to its Class A common stock with a $0.0001 par value per share. These RSUs will be settled in actual shares as they vest according to the specified schedule, rather than being immediately tradable stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 04:41 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Amir

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	02/24/2026		A(1)		64,191	A	$0	181,817	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting: 6.25% of the RSUs (rounded down to the nearest whole number) will vest every 3 months after March 8, 2026, with any remaining unvested RSUs to vest on March 8, 2030, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Melissa M. Tomkiel, Attorney-in-fact for Amir Cohen	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.